Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy

Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that typically predict benefit from PARP inhibitors. At the same time, the combination appears to stimulate type I interferon signaling and reduce PD‑L1 levels inside tumor cells, changes that can help the immune system better recognize and attack cancer.

Among the angiotensin receptor blockers tested, this effect seems unique to telmisartan rather than a class‑wide property, making telmisartan a specific repurposing candidate rather than just another blood‑pressure pill. Because telmisartan is generic, inexpensive, and familiar in cardiovascular medicine, it is particularly attractive as an add‑on to existing cancer drugs if the benefits are confirmed. Although the current evidence is still based mainly on laboratory work and is too early for routine use, a small clinical trial (NCT06168487) has already started at Dartmouth Cancer Center, testing telmisartan together with olaparib (and/or with other standard of care therapies) in men with metastatic castration‑resistant prostate cancer, with another trial underway in platinum‑resistant ovarian cancer. These early studies will help clarify whether the laboratory promise translates into real gains for patients.

Source.